Search research articles
Contact Us
Filters
Showing results (81-90 of 107) with videos related to
Page
of 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 24, 2016
Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution
Min Tang, Rui Zhao, Helgi van de Velde, et al.
Blood
|
October 30, 2010
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
Jacalyn Rosenblatt, Baldev Vasir, Lynne Uhl, et al.
Cancer
|
October 6, 2005
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
James R Berenson, Sundar Jagannath, Bart Barlogie, et al.
Cancer Research
|
March 7, 2014
miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway
Jian-Jun Zhao, Jianhong Lin, Di Zhu, et al.
British Journal of Haematology
|
March 8, 2011
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial
Paul Richardson, Rudolf Schlag, Nuriet Khuageva, et al.
British Journal of Haematology
|
July 6, 2017
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
Meletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
Frontiers in Oncology
|
December 19, 2023
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival
Rao Prabhala, William E Pierceall, Mehmet Samur, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 3, 2024
Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone
Omar Nadeem, Michelle P Aranha, Robert Redd, et al.
The Lancet. Oncology
|
May 18, 2019
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Paul G Richardson, Albert Oriol, Meral Beksac, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 14, 2013
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma
Luciano J Costa, Mei-Jie Zhang, Xiaobo Zhong, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 107) with videos related to
Sort By:
Page
of 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 24, 2016
Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution
Min Tang, Rui Zhao, Helgi van de Velde, et al.
Blood
|
October 30, 2010
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
Jacalyn Rosenblatt, Baldev Vasir, Lynne Uhl, et al.
Cancer
|
October 6, 2005
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
James R Berenson, Sundar Jagannath, Bart Barlogie, et al.
Cancer Research
|
March 7, 2014
miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway
Jian-Jun Zhao, Jianhong Lin, Di Zhu, et al.
British Journal of Haematology
|
March 8, 2011
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial
Paul Richardson, Rudolf Schlag, Nuriet Khuageva, et al.
British Journal of Haematology
|
July 6, 2017
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
Meletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
Frontiers in Oncology
|
December 19, 2023
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival
Rao Prabhala, William E Pierceall, Mehmet Samur, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 3, 2024
Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone
Omar Nadeem, Michelle P Aranha, Robert Redd, et al.
The Lancet. Oncology
|
May 18, 2019
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Paul G Richardson, Albert Oriol, Meral Beksac, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 14, 2013
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma
Luciano J Costa, Mei-Jie Zhang, Xiaobo Zhong, et al.
Page
of 11